Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Berkowitz

Showing results (411-420 of 497) with videos related to

Pageof 50
Sort By:
Circulation|May 6, 2024
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PADJustin T Morrison, Mario Enrico Canonico, Sonia S Anand, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|May 14, 2016
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AFAdam D DeVore, Anne S Hellkamp, Richard C Becker, et al.
Circulation|July 13, 2016
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation. Heart Failure|June 1, 2013
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AFSean van Diepen, Anne S Hellkamp, Manesh R Patel, et al.
Journal of the American Heart Association|October 30, 2018
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF TrialGene R Quinn, Anne S Hellkamp, Graeme J Hankey, et al.
Circulation|December 18, 2015
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationJonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Journal of the American Heart Association|September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF TrialAnthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Cardiology and Therapy|August 4, 2019
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AFLeo Ungar, Fatima Rodriguez, Anne S Hellkamp, et al.
Pageof 50

Showing results (411-420 of 497) with videos related to

Sort By:
Pageof 50
Circulation|May 6, 2024
Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PADJustin T Morrison, Mario Enrico Canonico, Sonia S Anand, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|May 14, 2016
Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AFAdam D DeVore, Anne S Hellkamp, Richard C Becker, et al.
Circulation|July 13, 2016
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation"Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Circulation. Heart Failure|June 1, 2013
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AFSean van Diepen, Anne S Hellkamp, Manesh R Patel, et al.
Journal of the American Heart Association|October 30, 2018
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF TrialGene R Quinn, Anne S Hellkamp, Graeme J Hankey, et al.
Circulation|December 18, 2015
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationJonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Clinical Cardiology|February 2, 2018
Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trialAjar Kochar, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Journal of the American Heart Association|September 27, 2021
Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF TrialAnthony P Carnicelli, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Cardiology and Therapy|August 4, 2019
Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AFLeo Ungar, Fatima Rodriguez, Anne S Hellkamp, et al.
Pageof 50